Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon halys hemocoagulase under Suling trade name. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors. The company was founded in 2003 and is headquartered in Beijing, China.
Research context
Beijing Konruns Pharmaceutical Co.,Ltd appears in PyInvesting’s Shanghai Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Beijing Konruns Pharmaceutical Co.,Ltd is currently in a long term downtrend where the price is trading 3.3% below its 200 day moving average.
From a valuation standpoint, the stock is 29.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.8.
Beijing Konruns Pharmaceutical Co.,Ltd's total revenue sank by 15.1% to $259M since the same quarter in the previous year.
Its net income has dropped by 33.3% to $42M since the same quarter in the previous year.
Finally, its free cash flow fell by 148.0% to $-24M since the same quarter in the previous year.
Based on the above factors, Beijing Konruns Pharmaceutical Co.,Ltd gets an overall score of 1/5.